Activation of endogenous type I IFN signaling contributes to persistent HCV infection

Abstract excerpt

HCV infection is a major world health problem, leading to both end-stage liver disease and primary liver cancer. Great efforts have been made in developing new therapies for HCV infection; however, combination therapy with pegylated IFN-α and ribavirin (pegIFN-RBV) remains the first choice of treatment for chronic HCV infection in most countries. The treatment response to pegIFN-RBV remains relatively low....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hepatitis C virus research
• Share to interferon and immune responses
• Share to Systemic Lupus Erythematosus Research